Login to Your Account

Galena Prices $35M Offering to fund Breast Cancer Drug

By Catherine Shaffer
Staff Writer

Friday, September 13, 2013
Galena Biopharma Inc. priced an underwritten public offering of 17.5 million units of stock at $2 per unit, for gross proceeds of $35 million. The funds will be used for commercialization of Abstral (fentanyl) sublingual tablets, and to support an ongoing Phase III trial of Neuvax.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription